Joint ENGOT and GOG Foundation requirements for trials with industry partners-Reference-Cited by-同舟云学术

Joint ENGOT and GOG Foundation requirements for trials with industry partners

Published:2019-07-18 Issue:7 Volume:29 Page:1094-1097
ISSN:1048-891X
Container-title:International Journal of Gynecologic Cancer
language:en
Short-container-title:Int J Gynecol Cancer

Author:

Vergote Ignace^ORCID,Coleman Robert L,Pignata Sandro,Bookman Michael A,Marth Christian,Herzog Thomas J,Gonzalez Martin Antonio,Copeland Larry J

Publisher

BMJ

Subject

Obstetrics and Gynecology,Oncology

Reference4 articles.

1. European Network of gynaecological oncological trial groups' requirements for trials between academic groups and pharmaceutical companies;Vergote;Int J Gynecol Cancer,2010

2. Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials

3. European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015

4. The Gynecologic Oncology Group . The Gynecologic Oncology Group: 43 years of success, 2018. Available: http://www.gog.org/AboutUs/GOG%2043rd%20Anniversary%20Pub.pdf [Accessed 21 Nov 2018].

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial;Annals of Oncology;2024-09

2. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study;Journal of Clinical Oncology;2023-12-20

3. The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization;International Journal of Gynecologic Cancer;2023-03-13

4. The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization;Journal of Gynecologic Oncology;2023

5. Early termination of pivotal trials in Alzheimer's disease—Preserving optimal value for participants and science;Alzheimer's & Dementia;2022-02-27